Who has invested in Axbio?

AstraZeneca-CICC Healthcare Industry Fund, Yunfeng Capital, CBC Group, SDIC, 5Y Capital are named among the investors backing Axbio.

Axbio Funding: $100M Raised, Series B (2022)

Axbio funding overview

Axbio is based in Shenzhen, China. Axbio has raised $100M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series B announced in June 2022. The round record for Axbio runs through 2022; nothing later has been disclosed. Investors on record include AstraZeneca-CICC Healthcare Industry Fund, Yunfeng Capital, CBC Group, SDIC, 5Y Capital. 5 distinct backers are named across the disclosed rounds.

Axbio at a glance

Total raised: $100M
Latest round: Series B
Latest round date: June 2022
Headquarters: Shenzhen, China
Notable investors: AstraZeneca-CICC Healthcare Industry Fund, Yunfeng Capital, CBC Group, SDIC, 5Y Capital

Frequently asked about Axbio funding

How much has Axbio raised?: Axbio has raised $100M in total disclosed funding across the rounds on record.
Who has invested in Axbio?: AstraZeneca-CICC Healthcare Industry Fund, Yunfeng Capital, CBC Group, SDIC, 5Y Capital are named among the investors backing Axbio.
What was the latest Axbio funding round?: The most recent disclosed round is a Series B, announced in June 2022.
Where is Axbio based?: Axbio is based in Shenzhen, China.
When did Axbio last raise?: The last disclosed Axbio round closed in June 2022 at Series B.

Round data for Axbio is compiled from public filings and announcements; blank fields mean nothing has been disclosed rather than nothing exists. Continue with the companies in Shenzhen and backer lists below.

Axbio Funding: $100M Raised, Series B (2022)

Axbio funding overview

Axbio at a glance

Frequently asked about Axbio funding

Companies related to Axbio (18)

Browse related funding lists (6)